Core 2: Immune Bioinformatics and Computational Biology Core

核心2:免疫生物信息学和计算生物学核心

基本信息

  • 批准号:
    10251175
  • 负责人:
  • 金额:
    $ 16.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-19 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY (IMMUNE BIOINFORMATICS AND COMPUTATIONAL BIOLOGY CORE) The overall goal of this P01 proposal is to apply a systematic approach to understanding mechanisms of immune resistance that can guide the rational design of novel combinatorial immunotherapies to effectively treat head and neck squamous cell carcinoma (HNSCC) patients. To accomplish this goal, we will use several cutting-edge bioinformatics strategies on data from bulk and single cell RNA sequencing (scRNA-seq), epigenomics assays, and exome sequencing, as well as biostatistics analysis of clinical trial data. Our team has complementary expertise encompassing HNSCC genetics and biology, innate and adaptive immune response, immune bioinformatics, single cell dynamics and the analysis of scRNA-seq, cancer epigenomics and genome-wide regulatory data, and HNSCC clinical trial data analyses. The objective of the Immune BioInformatics and Computational Biology (IBCB) Core is to provide, disease-specific comprehensive and innovative support to the P01 investigators for the study design, analysis, integration and interpretation of a broad range of omics-based and clinical trial studies. The IBCB Core will support the three projects of the P01 through four specific aims. First, we will recommend strategies for study design and provide analyses specific to immune bioinformatics. This includes, but is not limited to, mutational burden analysis and neoantigen prediction, analysis of HLA class I alleles, and immune cell type deconvolution. The second aim is to provide expertise for study design and perform various analyses and methods development for single cell bioinformatics. We will utilize several recently developed scRNA-seq methods for QC, batch correction and normalization, imputation, innovative visualizations, automatic cell type identification, and differential expression testing. The third aim is to provide consultation on experimental design and provide analyses for epigenomics data. We will analyze genome-wide DNA methylation and transcriptomics data before and after different immune checkpoint blockade (ICB) therapeutic regimens. Aim four is to provide advanced biostatistics and bioinformatics support for clinical trial analyses, power analyses, and other bioinformatics support not mentioned above, including data management, transparency, and data sharing.
项目总结(免疫生物信息学和计算生物学核心)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ramnik J Xavier其他文献

MIT Open Access Articles Gene networks that compensate for crosstalk with crosstalk
麻省理工学院开放获取文章用串扰补偿串扰的基因网络
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Springer Science;Business Media;Isaak E. Müller;Jacob R. Rubens;Tomi Jun;Daniel Graham;Ramnik J Xavier;Timothy K. Lu
  • 通讯作者:
    Timothy K. Lu

Ramnik J Xavier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ramnik J Xavier', 18)}}的其他基金

Cardiovascular disease, metabolic syndrome, microbes and metabolites in FHS
FHS 中的心血管疾病、代谢综合征、微生物和代谢物
  • 批准号:
    10367105
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cardiovascular disease, metabolic syndrome, microbes and metabolites in FHS
FHS 中的心血管疾病、代谢综合征、微生物和代谢物
  • 批准号:
    10556439
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
Core 2: Immune Bioinformatics and Computational Biology Core
核心2:免疫生物信息学和计算生物学核心
  • 批准号:
    10020930
  • 财政年份:
    2019
  • 资助金额:
    $ 16.62万
  • 项目类别:
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
RP2:自噬依赖性抑制细菌感染的靶向基因和途径
  • 批准号:
    10364724
  • 财政年份:
    2019
  • 资助金额:
    $ 16.62万
  • 项目类别:
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
RP2:自噬依赖性抑制细菌感染的靶向基因和途径
  • 批准号:
    10573259
  • 财政年份:
    2019
  • 资助金额:
    $ 16.62万
  • 项目类别:
Functional characterization of CARD9 genetic variants in fungal immunity
CARD9 遗传变异在真菌免疫中的功能表征
  • 批准号:
    10331807
  • 财政年份:
    2018
  • 资助金额:
    $ 16.62万
  • 项目类别:
Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital
马萨诸塞州总医院炎症性肠病研究中心
  • 批准号:
    9262326
  • 财政年份:
    2016
  • 资助金额:
    $ 16.62万
  • 项目类别:
Bacterial Dysbiosis in IgG4-RD
IgG4-RD 中的细菌生态失调
  • 批准号:
    8732925
  • 财政年份:
    2014
  • 资助金额:
    $ 16.62万
  • 项目类别:
ATG16L1 T300A: genetics to biology
ATG16L1 T300A:遗传学到生物学
  • 批准号:
    8588317
  • 财政年份:
    2013
  • 资助金额:
    $ 16.62万
  • 项目类别:
ATG16L1 T300A: genetics to biology
ATG16L1 T300A:遗传学到生物学
  • 批准号:
    8421941
  • 财政年份:
    2013
  • 资助金额:
    $ 16.62万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 16.62万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 16.62万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 16.62万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 16.62万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 16.62万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 16.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了